feraheme Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Feraheme, and when can generic versions of Feraheme launch?

Feraheme is a drug marketed by Covis and is included in one NDA.

The generic ingredient in FERAHEME is ferumoxytol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ferumoxytol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Feraheme

A generic version of feraheme was approved as ferumoxytol by SANDOZ on January 15^th, 2021.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for feraheme?
What are the global sales for feraheme?
What is Average Wholesale Price for feraheme?

Summary for feraheme

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	60
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for feraheme
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for feraheme
What excipients (inactive ingredients) are in feraheme?	feraheme excipients list
DailyMed Link:	feraheme at DailyMed

Drug patent expirations by year for feraheme

Recent Clinical Trials for feraheme

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	Early Phase 1
Lipella Pharmaceuticals, Inc.	Early Phase 1
Christopher J Chermansky, MD	Early Phase 1

See all feraheme clinical trials

Pharmacology for feraheme

Drug Class	Parenteral Iron Replacement

Paragraph IV (Patent) Challenges for FERAHEME

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FERAHEME	Injection	ferumoxytol	30 mg/mL, 17 mL single-use vials	022180	1	2015-12-04

US Patents and Regulatory Information for feraheme

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	FERAHEME	ferumoxytol	SOLUTION;INTRAVENOUS	022180-001	Jun 30, 2009	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for feraheme

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis	FERAHEME	ferumoxytol	SOLUTION;INTRAVENOUS	022180-001	Jun 30, 2009	⤷ Sign Up	⤷ Sign Up
Covis	FERAHEME	ferumoxytol	SOLUTION;INTRAVENOUS	022180-001	Jun 30, 2009	⤷ Sign Up	⤷ Sign Up
Covis	FERAHEME	ferumoxytol	SOLUTION;INTRAVENOUS	022180-001	Jun 30, 2009	⤷ Sign Up	⤷ Sign Up
Covis	FERAHEME	ferumoxytol	SOLUTION;INTRAVENOUS	022180-001	Jun 30, 2009	⤷ Sign Up	⤷ Sign Up
Covis	FERAHEME	ferumoxytol	SOLUTION;INTRAVENOUS	022180-001	Jun 30, 2009	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

EU/EMA Drug Approvals for feraheme

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharma A/S	Rienso	ferumoxytol	EMEA/H/C/002215 Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD).The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).	Withdrawn	no	no	no	2012-06-15
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for feraheme

See the table below for patents covering feraheme around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	2002541218		⤷ Sign Up
Japan	2011046752	HEAT STABLE COLLOIDAL IRON OXIDE COATED WITH REDUCED CARBOHYDRATE AND CARBOHYDRATE DERIVATIVE	⤷ Sign Up
Germany	60043188		⤷ Sign Up
Cyprus	1109527		⤷ Sign Up
World Intellectual Property Organization (WIPO)	0061191		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for feraheme

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1169062	92114	Luxembourg	⤷ Sign Up	PRODUCT NAME: FERUMOXYTOL
1169062	CA 2012 00050	Denmark	⤷ Sign Up
1169062	C01169062/01	Switzerland	⤷ Sign Up	PRODUCT NAME: FERUMOXYTOL; REGISTRATION NO/DATE: SWISSMEDIC 62033 17.08.2012
1169062	2012C/052	Belgium	⤷ Sign Up	PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620
1169062	1290043-7	Sweden	⤷ Sign Up	PRODUCT NAME: FERUMOXYTOL; REG. NO/DATE: EU/1/12/774/001 20120615
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description